{
    "root": "bfce7474-c519-494b-88c3-2d03bcaf0e43",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lubiprostone",
    "value": "20250317",
    "ingredients": [
        {
            "name": "LUBIPROSTONE",
            "code": "7662KG2R6K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01046"
        },
        {
            "name": "MEDIUM-CHAIN TRIGLYCERIDES",
            "code": "C9H2L21V7U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13959"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        }
    ],
    "indications": {
        "text": "lubiprostone chloride channel activator indicated treatment : chronic idiopathic constipation ( cic ) adults . ( 1.1 ) opioid-induced constipation ( oic ) adult patients chronic , non-cancer pain , including patients chronic pain related prior cancer treatment require frequent ( e.g . , weekly ) opioid escalation . ( 1.2 ) limitations : effectiveness lubiprostone treatment oic patients taking diphenylheptane opioids ( e.g . , methadone ) established . ( 1.2 , 7.1 ) irritable bowel syndrome constipation ( ibs-c ) women \u2265 18 years old . ( 1.3 )",
        "doid_entities": [
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "irritable bowel syndrome (DOID:9778)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9778"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic idiopathic constipation",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_648919"
            },
            {
                "disease": "chronic pain related",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_119281"
            }
        ]
    },
    "contraindications": {
        "text": "recommended ( 2.1 ) cic oic : 24 mcg twice daily . ibs-c : 8 mcg twice daily . full prescribing information adjustment indication degree hepatic impairment . instructions ( 2.2 ) swallow capsules whole break apart chew , take capsules food water , assess periodically need continuous therapy .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "lubiprostone available oval , soft gelatin capsule containing 8 mcg 24 mcg lubiprostone `` spi `` printed one side . lubiprostone available follows : 8 mcg pink capsule bottles 60 ( ndc 0406-6408-60 ) 24 mcg orange capsule bottles 60 ( ndc 0406-6424-60 )",
    "adverseReactions": "lubiprostone contraindicated patients known suspected mechanical gastrointestinal obstruction [ ( 5.5 ) ] .",
    "indications_original": "Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women \u2265 18 years old. ( 1.3 )",
    "contraindications_original": "Recommended Dosage ( 2.1 ) CIC and OIC: 24 mcg twice daily. IBS-C: 8 mcg twice daily. See full prescribing information for dosage adjustment by indication and degree of hepatic impairment. Administration Instructions ( 2.2 ) Swallow capsules whole and do not break apart or chew, Take capsules with food and water, Assess periodically the need for continuous therapy.",
    "warningsAndPrecautions_original": "Lubiprostone is available as an oval, soft gelatin capsule containing 8 mcg or 24 mcg of lubiprostone with \"SPI\" printed on one side. Lubiprostone is available as follows:\n                  8 mcg pink capsule\n                  \n                     Bottles of 60 (NDC 0406-6408-60)\n                  \n                  24 mcg orange capsule\n                  \n                     Bottles of 60 (NDC 0406-6424-60)",
    "adverseReactions_original": "Lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction [see Warnings and Precautions (5.5)].",
    "drug": [
        {
            "name": "Lubiprostone",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01046"
        }
    ]
}